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CASE REPORT
Lamivudine has become a main therapeutic option
for treating hepatitis B virus (HBV) infection.1–5
Its antiviral effects against HBV have been estab-
lished both in vitro and in vivo.6–8 Clinical trials
revealed that lamivudine is effective in reducing
HBV replication and preventing the progression
of chronic liver disease.4,5,9,10 Although complete
suppression of viral replication, as determined by
negative serum HBV DNA, may be achieved in
most patients, clearance of hepatitis B virus e anti-
gen (HBeAg) with antibody (anti-HBe) serocon-
version occurred only in a minority of patients.1,3,5
In Asian patients, HBeAg seroconversion with loss
of HBV DNA as detected by hybridization tech-
niques occurred in 16%, 27%, 40% and 47% after
1, 2, 3 and 4 years of treatment, respectively.4,9,11,12
Importantly, resistance to lamivudine therapy also
increased in frequency with continuation of ther-
apy, with detection rates of 17%, 40%, 55% and
67% after 1, 2, 3 and 4 years of treatment, respec-
tively.11,12 wOne mechanism responsible for the lo
sustained response (SR) rate to lamivudine ther-
apy may be the development of mutations in the
tyrosine-methionine-aspartate-aspartate (YMDD)
Vmotif of the reverse transcriptase domain of HB
tDNA polymerase. However, some patients withou
YMDD mutation still responded poorly to the
therapy. Pretreatment alanine aminotransferase
(ALT) levels, infection with HBV genotype B, age
less than 36 years and additional lamivudine
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treatment over 8 months have been shown to
be important determinants of SR to lamivudine
therapy.12,13
At least eight genotypes of HBV have been dis-
tinguished based on a divergence over the entire
genomic sequence of > 8% and designated A to
H.14–16 These genotypes have distinct geographical
distribution. Molecular epidemiologic studies
have indicated the existence of mixed infection
of different HBV genotypes in chronic hepatitis B
(CH-B) carriers.17,18 A high prevalence of mixed
genotype infections has been reported in HBV-
infected intravenous drug users.19 It has also been
shown that in HBV genotypes B and C co-infected
patients, recombination between different HBV
genotypes are not unusual.20 The impact of recom-
bination on HBV evolution and the clinical sig-
nificance of mixed genotype infection remain to
be elucidated. Here, we report four CH-B patients
with dual HBV genotype B and C infection who
received lamivudine monotherapy for 18 months.
None of them achieved a sustained response dur-
ing the 18-month trial of treatment.
Methods
Case identification
A total of 175 consecutive CH-B patients positive
for HBeAg with acute exacerbation (AE) partici-
pated in a nationwide therapeutic trial of 18-
month lamivudine therapy in Chi Mei Medical
Center (CMMC, Tainan, Taiwan). The initial 40
cases were recruited from the outpatient clinics
of eight physicians at CMMC. All these patients
completed the 18-month treatment course and
post therapy follow-up for more than 6 months.
Four of the patients with nonresponse to therapy
were found to be co-infected with HBV geno-
types B and C by INNO-LiPA HBV genotyping
(Innogenetics NV, Belgium). This report describes
the clinical courses of these patients during the
18-month trial of lamivudine.
AE was defined as an abrupt increase of serum
ALT levels (upper limit of normal, 40 U/L) to a
level greater than five times the upper limit of
normal (200 U/L).21,22 Before the treatment, all
fpatients met the following criteria: presence o
hepatitis B surface antigen (HBsAg) and HBeAg in
serum for at least 6 months; with AE of CH-B, i.e.,
ALT > t200 U/L; seropositivity for HBV DNA on a
least two occasions 1 month apart before entry;
and undetectable YMDD mutants. None of the
patients had concurrent hepatitis C virus (HCV),
hepatitis delta virus (HDV) or human immun-
odeficiency virus (HIV) infection.
Oral lamivudine (Zeffix; GlaxoWellcome,
Greenford, UK) 100 mg/day was administered
for 18 months as recommended by the National
Health Insurance Program of Taiwan (NHIT)
yand the cost of medication was fully covered b
 the NHIT. SR to the treatment was defined as
 a sustained loss of HBeAg with seroconversion
fto anti-HBe, together with the disappearance o
serum HBV DNA (virological response), and
with the normalization of serum ALT levels (bio-
fchemical response). A transient normalization o
rserum ALT levels followed by a relapse eithe
after the end of treatment or during lamivudine
therapy was defined as partial response (PR).
f Nonresponse (NR) was defined as the lack o
either a biochemical or a virological response to
the therapy.
Follow-up
Patients with AE were treated with oral lamivu-
dine and followed up weekly or biweekly. Hospital
care was recommended for patients with severe
AE as it may be associated with hepatic decom-
pensation or failure.16 After episodes of AE, patients
were followed up monthly with continuing lami-
vudine therapy. Routine follow-up studies were
performed including clinical assessment, con-
ventional liver biochemical tests, and virological
assays. All biochemical tests were carried out in
the clinical pathology laboratories of CMMC with
routine automated techniques.
Virological assays
HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HDV, anti-
HIV-1, and anti-HIV-2 were assayed using commer-
cially available ELISA kits (Abbott Laboratories,
fLamivudine therapy in dual HBV genotype in ection
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North Chicago, IL, USA; Ortho Diagnostic Systems,
Raritan, NJ, USA; and Sanofi Diagnostic Pasteur,
Marnes-la Coquette, France). Serum IgM anti-
HBc was assayed using a microparticle enzyme
immunoassay kit (AxSYM CORE-MTM, Abbott Lab-
oratories). Serum antibodies to hepatitis C virus
were assayed using a third-generation enzyme
immunoassay kit (AxSYM HCV, Version 3.0,
Abbott Laboratories). Serum HBV DNA was
quantified using a hybrid capture assay (Digene
Hybrid Capture II HBVDNA Test, Digene Corp.,
Gaithersburg, MD, USA). The detection limit of
HBV DNA by this assay is 0.5 pg/mL or 1.4 × 105
copies/mL.
HBV genotyping and YMDD mutation assay
HBV genotyping was performed by INNO-
LiPA HBV genotyping, according to the manufac-
turer’s instructions. Although line probe assay was
shown to be more sensitive than polymerase chain
reaction-restriction fragment length polymorphism
(PCR-RFLP) assay in identifying HBV genotype,19
the line probe assay INNO-LiPA kit can only 
detect the seven HBV genotypes A–G. We therefore
conducted PCR-RFLP assay in parallel as mutual
confirmation of the HBV genotypes A–G and to
detect other possible mixed genotype infections. In
brief, primers (sense, 5’-GTGGTGGACTTCTCT-
CAATTTTC(256–278); anti-sense, 5’-CGGTA(A/T)
AAAGGGACTCA(A/C)GAT(796–776)) were used
to amplify S gene from patients’ serum and the
geneclean DNA of PCR products was digested
with restriction enzymes TSP 509 I and Hinf I.23,24
YMDD mutants were also detected using the
INNO-LiPA HBV DR kit, and confirmed by DNA
sequencing of PCR products from each serum
sample using the CEQ2000 DNA Analysis System
(Beckman Coulter, Inc., Fullerton, CA, USA). To
avoid false positive results, instructions to prevent
cross contamination were strictly followed. In ad-
dition, an aliquot of HBV-positive serum containing
108 copies/mL of HBV DNA was serially diluted
and used as the standard for HBV DNA quantita-
tion and for determination of the sensitivity of
HBV genotyping. The sensitivity of these two assays
approximated 100 copies of HBV DNA.
Results
rFigure 1 shows the clinical courses of the fou
patients infected with dual HBV genotype B and C
viruses. Although transient biochemical responses
were achieved in cases 2 and 3, their ALT levels
rrelapsed eventually. HBV genotyping of the fou
patients compared with six consecutive patients
with single HBV genotype infection is shown in
Figure 2. No patient with dual HBV genotype in-
fection achieved HBeAg clearance or seroconver-
ysion, or loss of serum HBV DNA as determined b
fhybrid capture assay during the 18 months o
lamivudine therapy. Case 4 also developed YMDD
mutation with appearance of YIDD mutant virus
tafter 18 months of lamivudine treatment (data no
Tshown). Post therapy normalization of serum AL
tlevels or loss of HBV DNA was not detected a
follow-up for more than 6 months after the end
of treatment (data not shown in Figure 1).
Discussion
HBV infection is a global challenge with an esti-
mated worldwide distribution of 350 million
chronic carriers.25 kAll of these patients are at ris
of developing adverse sequelae, including chro-
rnic hepatitis, liver cirrhosis, and hepatocellula
carcinoma (HCC).
It is implicated that HBV genotypes may influ-
ence the clinical outcomes of CH-B patients. The
clinical significance of different HBV genotypes
in patients with both acute and chronic HBV infec-
rtions has become increasingly recognized. Fo
example, genotype C is more commonly associ-
ated with the progression of liver diseases, whereas
genotype B may also be associated with the 
cdevelopment of HCC in young noncirrhoti  
patients.26–28 In addition, genotype C has a
higher frequency of core promoter mutation and
a lower response rate to interferon therapy com-
pared to genotype B.29,30 Genotypes C and D are
associated with a lower response rate to interferon
therapy compared with genotypes B and A.29 A
correlation between HBV genotype and response
fLamivudine therapy in dual HBV genotype in ection
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iF gure 1. f f fClinical courses o  the our patients in ected with dual HBV genotype B and C: (A) Case 1: 39-year-old male; (B) Case 2: 29-year-
old male; (C) Case 3: 35-year-old male; (D) Case 4: 33-year-old male. Time points (3, 3, 2 and 2 for cases 1, 2, 3 and 4, respectively) for
detection of YMDD variants in serum by INNO-LiPA HBV DR kit (data not shown) are indicated on the figures. 3-TC = lamivudine; M =
YMDD wildtype virus; I = YIDD mutant virus.
iF gure 2. f fINNO-LiPA HBV genotyping. The typing results were con irmed by using polymerase chain reaction-restriction ragment length
polymorphism assay of the surface gene of HBV DNA fragment (541 bp; nt 256–796).
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to lamivudine or adefovir dipivoxil therapy has
not been demonstrated.31,32 Several studies in Asia,
all involving small patient numbers and varying
durations of lamivudine treatment, showed that
HBeAg seroconversion and breakthrough infection
occurred in similar proportions of patients with
genotypes B and C.12,13,31,32
Kato et al explored the mechanism by which
HBV genotype G, which has two stop codons in
the precore region, maintains HBeAg production.33
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They found all four patients with HBV genotype
G, who were HBeAg positive, were also co-infected
with HBV genotype A. The clinical significance of
mixed HBV genotype infection remains unclear.
All four CH-B patients with dual HBV genotype
B and C infection and with AE did not respond
to an 18-month course of lamivudine monother-
apy. Thus, a longer duration of monotherapy may
be required or combination with other treatment
modalities should be considered. Effective treat-
ment of these patients, however, may require
tremendous medical expenditure, and further
analysis of cost vs. benefit of treatment modali-
ties is required to determine the indicated course
of treatment for CH-B patients with dual geno-
type B and C infection and AE.
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